- In 2019, Boston Scientific Corporation (US) launched Vercise PC and Vercise Gevia Deep Brain Stimulation (DBS) Systems, featuring the Vercise Cartesia Directional Lead.
This report aims to provide detailed insights into the Neurosurgery Devices Market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.
Expected Revenue Growth Analysis:
The global Neurosurgery Instruments Market is projected to reach USD 13.5 billion by 2024 from USD 7.3 billion in 2019, at a CAGR of 13.0% during the forecast period.
Download PDF Brochure:
Key Factors Driving Market Growth:
The major factors driving the growth of the Neurosurgery Devices Market are the rising prevalence of neurological disorders, the benefits of neuroendoscopic surgeries over conventional brain surgeries, and the growing prevalence of neurological diseases.
The competitive landscape includes the analysis of the key growth strategies adopted by major players to expand their global presence and increase their shares in the market. The key growth strategies adopted by the top players in the market include product launches and approvals, agreements, expansions, and acquisitions. Product approvals and launches were the most widely adopted growth strategies by market players in the last three years to garner a larger share of the market.
- B. Braun Melsungen (Germany),
- Medtronic (US),
- Boston Scientific Corporation (US),
- Nevro Corporation (US),
- KARL STORZ (Germany),
- Abbott (US),
- Ackermann Instrumente (Germany)
Get more crucial industry insights:
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.